Literature DB >> 25766722

Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.

Norma Palma1, John C Morris2, Siraj M Ali1, Jeffrey S Ross3, Sumanta Kumar Pal4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25766722     DOI： 10.1016/j.eururo.2015.02.023

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  9 in total

1.  Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma.

Authors:  Hiroshi Kobayashi; Tomotake Okuma; Hiroyuki Oka; Toshihide Hirai; Takahiro Ohki; Masachika Ikegami; Ryoko Sawada; Yusuke Shinoda; Toru Akiyama; Kenji Sato; Satoshi Abe; Hirotaka Kawano; Takahiro Goto; Sakae Tanaka
Journal:  Int J Clin Oncol       Date:  2017-10-31       Impact factor: 3.402

2.  Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion-Positive Metastatic Urothelial Carcinoma.

Authors:  Amin H Nassar; Kevin Lundgren; Jaegil Kim; Toni K Choueiri; Guru P Sonpavde; David J Kwiatkowski; Joaquim Bellmunt
Journal:  JCO Precis Oncol       Date:  2018-07-24

3.  Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.

Authors:  Sasinya N Scott; Irina Ostrovnaya; Caroline M Lin; Nancy Bouvier; Bernard H Bochner; Gopakumar Iyer; David Solit; Michael F Berger; Oscar Lin
Journal:  Cancer Cytopathol       Date:  2017-03-24       Impact factor: 5.284

4.  Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma.

Authors:  Patrizia Pinciroli; Helen Won; Gopa Iyer; Silvana Canevari; Maurizio Colecchia; Patrizia Giannatempo; Daniele Raggi; Marco A Pierotti; Filippo G De Braud; David B Solit; Jonathan E Rosenberg; Michael F Berger; Andrea Necchi
Journal:  Clin Genitourin Cancer       Date:  2015-08-07       Impact factor: 2.872

Review 5.  Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.

Authors:  M N Pham; A B Apolo; M De Santis; M D Galsky; B C Leibovich; L L Pisters; A O Siefker-Radtke; G Sonpavde; G D Steinberg; C N Sternberg; S T Tagawa; A Z Weizer; M E Woods; M I Milowsky
Journal:  World J Urol       Date:  2016-06-24       Impact factor: 4.226

Review 6.  A place for precision medicine in bladder cancer: targeting the FGFRs.

Authors:  Erica di Martino; Darren C Tomlinson; Sarah V Williams; Margaret A Knowles
Journal:  Future Oncol       Date:  2016-07-06       Impact factor: 3.404

7.  Assessment of potential predictive value of peripheral blood inflammatory indexes in 26 cases with soft tissue sarcoma treated by pazopanib: a retrospective study.

Authors:  Cem Mirili; Semra Paydaş; Isa B Guney; Ali Ogul; Serkan Gokcay; Mahmut Buyuksimsek; Abdullah E Yetisir; Bilgin Karaalioglu; Mert Tohumcuoglu; Gulsah Seydaoglu
Journal:  Cancer Manag Res       Date:  2019-04-23       Impact factor: 3.989

8.  Dramatic Responses of Recurrent Upper Urinary Tract Urothelial Carcinoma Harboring FGFR3 and TP53 Activating Mutations to Pembrolizumab in Combination with Erdafitinib: A Case Report.

Authors:  Xinjia Ding; Jianguo Zong; Xiang Li; Xiaoyan Bai; Bowen Tan; Weibing Sun; Ruoyu Wang; Yan Ding
Journal:  Onco Targets Ther       Date:  2021-03-25       Impact factor: 4.147

9.  CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.

Authors:  Thomas S Worst; Cleo-Aron Weis; Robert Stöhr; Simone Bertz; Markus Eckstein; Wolfgang Otto; Johannes Breyer; Arndt Hartmann; Christian Bolenz; Ralph M Wirtz; Philipp Erben
Journal:  Sci Rep       Date:  2018-09-26       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.